Genetics Institute LLC

AUSTIN, Texas--(BUSINESS WIRE)-- PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors. “John has been an outstanding addition to our Board and management team since joining the company in September. We look forward to further benefiting from his experience as we continue to advance our lead program, PTM-101, into later stage clinical trials,” said Laura Indolfi, PhD, Chief Executive Officer and co-founder of PanTher. “John has successfully guided many biotech companies through key stages in their evolution and he is a tremendous resource for our organization.” John brings over 35 years of experience in discovery, development, and global commercialization of biopharmaceuticals to PanTher. His experience includes involvement with ten FDA approved biologics and eight biotech companies with successful exits, including Tilos Therapeutics, Siamab, Adnexus, F-star and Genetics Institute. Most recently, John held the role of Executive Chair and CEO at Abcuro, where he transformed the small preclinical-stage company into a well-funded organization with a highly experienced C-suite, and advanced its lead program into a phase III clinical trial. During his time as Executive Chair at Tilos, he helped the company from founding to acquisition by Merck in just two years. While at F-star, John helped grow the company from discovery-stage into to a leading clinical-stage developer of bispecific antibodies, raising over $230M in non-dilutive capital, including several asset-based M&A transactions. Under his guidance as COO, Adnexus evolved from a start-up to a $450M acquisition by BMS within 4 years; he then continued as President of the company for three years. Early in his career, John was Vice President of Sales, Marketing, and Medical Affairs at Transkaryotic Therapies and had a 15-year tenure with Genetics Institute/Wyeth, during which time he built what has become a >$1B global pharmaceutical business in hematology. He received his MBA from Boston University and his BS in chemical engineering from the University of Massachusetts at Amherst. “I am very impressed with PanTher’s lead program and therapeutic platform, which I feel has the potential to be transformative for the treatment of locally advanced, solid tumors,” said John. “PanTher’s approach combines established cancer treatments, whose dosing is limited by toxicity, with their technology that enables continuous, high-dose, delivery to the tumor. In doing so, drug levels at the site of a tumor are >100 fold higher than what is currently possible, leading to more effective treatments without unwanted dose-limiting systemic side effects. This unlocks the full potential of potent therapeutic agents to more effectively treat cancer. I am excited to work with Laura, the management team, and Board to help guide the company’s future direction as it prepares to enter phase 1b clinical trials with its lead program.” About PanTher Therapeutics PanTher Therapeutics is a clinical-stage oncology company offering transformational localized treatment of cancer. This is accomplished through its proprietary Sagittari™ platform which enables continuous, high-dose treatment of potent oncology agents exclusively at the site of a tumor. The Sagittari™ treatment platform is a revolutionary solution for local administration of therapeutic agents. This foundational technology was invented at the Massachusetts Institute of Technology by PanTher’s founder and CEO. Sagittari is a polymer-based system that allows therapeutic agents to be formulated in a wide range of dosage forms that can be administered to the surface of a cancerous organ or implanted directly into a tumor. The drug product is designed to continuously deliver drug for weeks or months at a desired dose level, without unwanted dose-limiting side effects. PanTher’s lead clinical candidate, PTM-101, has successfully been evaluated in a Phase 1 clinical trial in treatment naïve localized non-metastatic pancreatic cancer patients. PanTher is exploring opportunities to utilize its platform technology in additional solid tumor indications. For more information, visit . About PTM-101 PanTher’s lead clinical candidate, PTM-101, is a proprietary flexible absorbable film that enables sustained, high-dose administration of paclitaxel directly to the peritumoral area, maximizing anti-tumor potency and avoiding the severe side effects typically seen with systemic administration of paclitaxel. PTM-101 was designed to easily integrate with well-established laparoscopic procedures that can be used for peritumoral placement. PTM-101 is being evaluated for the treatment of localized non-metastatic pancreatic cancer, where the company recently completed a successful phase 1 study. PanTher is now preparing to initiate a Phase 1b trial of PTM-101, to further assess safety, tolerability, and anti-tumor activity across two different dose levels. View source version on businesswire.com: Contacts Media: Christine Quern 617-650-8497 cq@christinequern.com Source: PanTher Therapeutics View this news release online at:

BERKELEY, Calif., Oct. 26, 2023 /PRNewswire/ - Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Steven Vicik, PhD, as Chief Technical Officer (CTO). Dr. Steven Vicik joins the company with over 25 years of experience in pharmaceutical process and product development, manufacturing operations, as well as supply chain design and distribution for large and small molecule drugs. In his role as CTO, he will lead and execute Actym's technology strategy and advance Actym's proprietary platform, S. Typhimurium-Attenuated Cancer Therapy (STACT), which represents a novel approach to achieving comprehensive immunological reprogramming of the tumor microenvironment (TME). The appointment comes after Actym recently announced a Series A extension that will support a Phase 1 clinical trial designed to achieve proof of mechanism for Actym's lead candidate, ACTM-838. "Welcoming Steve to Actym represents a valuable addition to our expert-led management team," said Dr. Christopher D. Thanos, President, CEO, and Co-founder of Actym. "With Steve contributing his technical expertise to our product development vision, we are well-equipped to translate our team's deep understanding of the tumor microenvironment into furthering our novel approach for effective and safe cancer treatments." Commenting on his appointment, Dr. Vicik added, "Actym is developing an innovative drug modality with exciting potential to reprogram the TME. It is a great opportunity to contribute to the development process of ACTM-838 as we move toward clinical evaluation." Dr. Steven Vicik has extensive experience in leading the development and manufacturing of multiple clinical assets. He has supported several successful Biologics License Application (BLA) and New Drug Application (NDA) registrations, resulting in global product launches. Additionally, he has coordinated manufacturing and distribution strategies for a drug portfolio that generates over $5B in sales annually. Before joining Actym, Dr. Vicik served as CTO at Xalud Therapeutics, a clinical-stage biotechnology company that specializes in developing a non-viral gene therapy platform. In this role, he oversaw process development, manufacturing, Chemistry Manufacturing and Control (CMC), and supply chain activities. Earlier in his career, Dr. Vicik held various leadership roles at Pfizer, Wyeth, and Genetics Institute, where he was responsible for both the development and the implementation of manufacturing and supply chain enhancements. He is also the holder of several large molecule manufacturing patents. Dr. Vicik earned a Ph.D. in Chemical Engineering from Tufts University. About Actym Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered treatment that exploits intrinsic TME-specific metabolites, enabling selective enrichment of the bacterial vehicle in tumors. After cell-specific entry, our lead candidate, ACTM-838, positively activates tumor-resident myeloid cells and delivers two synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive anti-tumor immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types. Contacts For Actym Therapeutics Christopher Thanos, CEO E-Mail: [email protected] Media Requests for Actym Dr. Alison Opalko or Sara Ortiz Trophic Communications Phone: +49 151 54041130 or +49 160 90816161 E-Mail: [email protected] SOURCE Actym Therapeutics Inc.

Mr. Burgess will be responsible for leading Cerevel’s business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. “I am so pleased to welcome Paul to Cerevel as our chief business development and strategic operations officer, with his proven track record of success in the biotech and pharmaceutical industry,” said Ron Renaud, president and chief executive officer of Cerevel Therapeutics. “Paul brings more than 20 years of corporate development and operational experience to the organization, and his insights and expertise will be indispensable as we seek to become the premier neuroscience company.” “I look forward to joining Cerevel during this pivotal time and supporting the mission to transform the lives of people living with some of the most devastating neuroscience diseases,” said Mr. Burgess. “Cerevel’s patient-centered approach holds great promise for delivering new treatment options for schizophrenia, Parkinson’s disease, and epilepsy." About Paul Burgess Paul Burgess is a biotechnology executive with over 20 years of experience working at both start-up companies and larger pharmaceutical organizations. Mr. Burgess’s most recent role was chief operating officer and chief legal officer of Translate Bio. At Translate Bio, he led business development, legal, program management, quality, technical operations and partner collaborations. He joined Translate Bio in 2015 and remained until 2021, when the company was sold to Sanofi for $3.2 billion. Prior to Translate Bio, Mr. Burgess worked in a legal role at a number of companies including Scholar Rock, Civitas Therapeutics, BIND Therapeutics and Transform Pharmaceuticals. Earlier in his career, he also worked in the lab at Genetics Institute. About Cerevel Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases by combining its deep expertise in neurocircuitry with a focus on targeted receptor subtype selectivity and a differentiated approach to pharmacology. Cerevel Therapeutics has a diversified pipeline comprised of five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, and Parkinson’s disease. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about: the potential attributes and benefits of our product candidates and the format, timing and objectives of our product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19, the post-COVID environment and other factors on the timing, progress and results of clinical trials; our ability to recruit and enroll suitable patients in our clinical trials; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading “Risk Factors” in our Quarterly Report on Form 10-Q filed with the SEC on May 3, 2023 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Media Contact: Anna Robinson Cerevel Therapeutics anna.robinson@cerevel.com Investor Contact: Matthew Calistri Cerevel Therapeutics matthew.calistri@cerevel.com